. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: J Am Acad Dermatol. 2018 Jan 4;78(6):1068–1076. doi: 10.1016/j.jaad.2017.12.068

Table 3.

Comparison of demographics, clinical data, and outcomes between our cohort and literature cohort.

		Our cohort (n=22)	Literature cohort (n=31)
Male:Female		15:7	21:9, 1 not specified
Median age (range), *years*		63 (21 – 72)	63 (28 – 75)
Disease for anti-TNFα agents	Skin disease	16	11
Disease for anti-TNFα agents	Systemic disease^*	6	20
Anti-TNFa used		Adalimumab (14), etanercept (7), infliximab (4)	Infliximab (12), etanercept (11), adalimumab (8)
Skin biopsy prior to anti-TNFα agent used		15/18^**	11/16^**
CL diagnosis (number of patients)		MF/SS (15), CTCL NOS (3), Cytotoxic CTCL (2), CBCL (2)	MF/SS (19), Cytotoxic CTCL (5), CD30 CLPD (2), cutaneous HD (2), SM PTCL (2), ATLL (1)
Disease stage in MF/SS patients (number of patients)		IA (2), IB (1), IIB (4), IIIA (2), IVA (4)	IA or IB (13), IIB (2), IVA (4)
Median time of follow-up (range), *months*		25 (4 – 137)	11 (0.7 – 19)
Outcome (number of patients)		CR (9), PR (6), SD (3), PD (2)	CR (12), PR (9), SD (2), PD (1), Died (5)

Crohn’s disease, Rheumatoid arthritis, Spondyloarthropathy, psoriatic arthritis

^**

Skin biopsies/total of patients with skin disorder

TNFα: tumor necrosis factor alpha; MF: mycosis fungoides; SS: Sézary syndrome; CD30 CLPD: CD30 cutaneous lymphoproliferative disorder; SMPTCL: small/medium pleomorphic T-cell lymphoma; ATLL: adult T-cell lymphoma/leukemia, CR: complete remission; PR: partial response; SD: stable disease, PD: progressive disease.